UK Markets open in 7 hrs 45 mins

Chugai Pharmaceutical Co., Ltd. (CHGCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
32.70-0.52 (-1.57%)
At close: 02:09PM EST
Full screen
Trade prices are not sourced from all markets
Previous close33.22
Open33.23
BidN/A x N/A
AskN/A x N/A
Day's range33.22 - 33.22
52-week range32.13 - 46.25
Volume28
Avg. volume837
Market cap53.976B
Beta (5Y monthly)0.65
PE ratio (TTM)24.15
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.52 (1.57%)
Ex-dividend date29 Dec 2021
1y target estN/A
All
News
  • Business Wire

    New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

    TOKYO, October 14, 2021--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced new longer-term efficacy and safety data for Enspryng® [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. The data show Enspryng has a favourable benefit:risk profile and is effective in reducing relapses over four years of treatment in people with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spe

  • Business Wire

    Chugai’s Enspryng (Satralizumab) Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)

    TOKYO, June 28, 2021--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche has been granted Marketing Authorization from the European Commission for the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Enspryng® (satralizumab), created by Chugai, as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monoth

  • Business Wire

    CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Enspryng® (satralizumab), created by Chugai, as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST).